Latest news

China’s gene-editing landscape advances as CVC’s second CRISPR/Cas9 patent granted

China’s gene-editing landscape advances as CVC’s second CRISPR/Cas9 patent granted New patent covers methods and compositions for use of CRISPR/Cas9 in eukaryotes.   Dublin, Ireland, 09 November 2021: ERS Genomics Limited (‘ERS’) is pleased to report that China Patent No. 2017105856905 has been granted. This new patent covers methods and compositions for use of CRISPR/Cas9 in eukaryotes. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. With this patent in China, the fundamental value of gene-editing technology is officially validated within the scientific community. The patent covers methods and compositions

Read more <i class="fal fa-long-arrow-right"></i>
News

Top news